- Home
- ADV vs TYRA Comparison
ADV vs TYRA Comparison
Compare ADV & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADV
- TYRA
- Stock Information
- Founded
- ADV 1987
- TYRA 2018
- Country
- ADV United States
- TYRA United States
- Employees
- ADV N/A
- TYRA N/A
- Industry
- ADV Business Services
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- ADV Consumer Discretionary
- TYRA Health Care
- Exchange
- ADV Nasdaq
- TYRA Nasdaq
- Market Cap
- ADV 586.7M
- TYRA 681.7M
- IPO Year
- ADV N/A
- TYRA 2021
- Fundamental
- Price
- ADV $1.48
- TYRA $13.39
- Analyst Decision
- ADV Strong Buy
- TYRA Strong Buy
- Analyst Count
- ADV 1
- TYRA 7
- Target Price
- ADV $2.50
- TYRA $30.71
- AVG Volume (30 Days)
- ADV 725.1K
- TYRA 185.2K
- Earning Date
- ADV 11-06-2025
- TYRA 11-06-2025
- Dividend Yield
- ADV N/A
- TYRA N/A
- EPS Growth
- ADV N/A
- TYRA N/A
- EPS
- ADV N/A
- TYRA N/A
- Revenue
- ADV $3,527,054,000.00
- TYRA N/A
- Revenue This Year
- ADV N/A
- TYRA N/A
- Revenue Next Year
- ADV N/A
- TYRA N/A
- P/E Ratio
- ADV N/A
- TYRA N/A
- Revenue Growth
- ADV N/A
- TYRA N/A
- 52 Week Low
- ADV $1.04
- TYRA $6.42
- 52 Week High
- ADV $4.04
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- ADV 35.21
- TYRA 59.58
- Support Level
- ADV $1.44
- TYRA $12.98
- Resistance Level
- ADV $1.56
- TYRA $13.92
- Average True Range (ATR)
- ADV 0.07
- TYRA 0.62
- MACD
- ADV -0.03
- TYRA 0.00
- Stochastic Oscillator
- ADV 7.00
- TYRA 55.66
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.